Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

XERS

Xeris Biopharma Holdings Inc

Oct 24 • 04:00PM ET

9.21

+0.08 0.88 %

Healthcare • Biotechnology • USA • NASD

Peers: LGND ALKS BCRX SUPN AMRN ANIP MNKD RDHL ECOR

| Held by: VTI IWM VXF IWO SCHA VTWO VHT DWAS XPH IWC

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-0.21	Insider Own	6.18%	Shs Outstand	161.22M	Perf Week	-0.32%
Market Cap	1.49B	Forward P/E	37.94	EPS next Y	0.24	Insider Trans	-1.80%	Shs Float	151.50M	Perf Month	17.32%
Enterprise Value	1.69B	PEG	-	EPS next Q	0.01	Inst Own	56.73%	Short Float	11.78%	Perf Quarter	81.66%
Income	-32.00M	P/S	6.04	EPS this Y	94.69%	Inst Trans	3.49%	Short Ratio	7.10	Perf Half Y	113.69%
Sales	246.03M	P/B	-	EPS next Y	1336.44%	ROA	-9.60%	Short Interest	17.85M	Perf YTD	171.68%
Book/sh	-0.12	P/C	25.09	EPS next 5Y	-	ROE	-	52W High	9.40 -2.07%	Perf Year	204.97%
Cash/sh	0.37	P/FCF	-	EPS past 3/5Y	37.81% 40.01%	ROIC	-13.81%	52W Low	2.82 226.60%	Perf 3Y	648.78%
Dividend Est.	-	EV/EBITDA	615.03	Sales past 3/5Y	59.99% 136.89%	Gross Margin	77.83%	Volatility	3.66% 4.61%	Perf 5Y	66.85%
Dividend TTM	-	EV/Sales	6.85	EPS Y/Y TTM	49.58%	Oper. Margin	-3.99%	ATR (14)	0.38	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	1.24	Sales Y/Y TTM	35.62%	Profit Margin	-13.01%	RSI (14)	66.55	Recom	1.33
Dividend Gr. 3/5Y	- -	Current Ratio	1.95	EPS Q/Q	88.04%	SMA20	7.67%	Beta	0.50	Target Price	9.00
Payout	-	Debt/Eq	-	Sales Q/Q	48.84%	SMA50	13.96%	Rel Volume	0.71	Prev Close	9.13
Employees	394	LT Debt/Eq	-	Earnings	Nov 06 BMO	SMA200	68.63%	Avg Volume	2.51M	Price	9.21
IPO	Jun 21, 2018	Option/Short	Yes / Yes	EPS/Sales Surpr.	64.29% 11.02%	Trades		Volume	1,778,970	Change	0.88%

Date	Action	Analyst	Rating Change	Price Target Change
Aug-12-25	Resumed	H.C. Wainwright	Buy	$10
Nov-11-24	Downgrade	Piper Sandler	Overweight → Neutral	$3
Mar-28-24	Initiated	Oppenheimer	Outperform	$5
Aug-28-23	Initiated	Craig Hallum	Buy	$4.50
Oct-21-22	Initiated	Jefferies	Buy	$4
Apr-28-22	Initiated	Craig Hallum	Buy	$6.50
Nov-17-21	Initiated	SVB Leerink	Outperform	$6
Oct-29-21	Initiated	H.C. Wainwright	Buy	$4
Apr-07-21	Resumed	RBC Capital Mkts	Outperform	$11
Feb-18-20	Initiated	Piper Sandler	Overweight	$12
Jul-16-18	Initiated	RBC Capital Mkts	Outperform	$24
Jul-16-18	Initiated	Leerink Partners	Outperform	$24
Jul-16-18	Initiated	Jefferies	Buy	$23

Show Previous Ratings

Oct-23-25 07:30AM	Xeris Biopharma to Report Third Quarter 2025 Financial Results on November 6, 2025 (Business Wire)
Oct-20-25 12:00PM	Are You Looking for a Top Momentum Pick? Why Xeris Biopharma (XERS) is a Great Choice (Zacks)
09:15AM	Xeris Biopharma Holdings, Inc. (XERS) Hit a 52 Week High, Can the Run Continue? (Zacks)
Oct-16-25 09:06AM	Xeris Biopharma (XERS) Surges 14.2%: Is This an Indication of Further Gains? (Zacks)
Oct-13-25 07:58AM	Beat the Market the Zacks Way: MariMed, Xeris Biopharma, Lam Research in Focus (Zacks)
04:15PM	Loading…
Oct-03-25 04:15PM	Xeris Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
12:00PM	Xeris Biopharma (XERS) is a Great Momentum Stock: Should You Buy? (Zacks)
09:15AM	Xeris Biopharma Holdings, Inc. (XERS) Hits Fresh High: Is There Still Room to Run? (Zacks)
Sep-09-25 12:00PM	What Makes Xeris Biopharma (XERS) a Strong Momentum Stock: Buy Now? (Zacks)
Aug-29-25 05:09AM	Xeris Biopharma Holdings, Inc. (XERS) Reports Record $71.5M Q2 Revenue (Insider Monkey)
Aug-25-25 07:00AM	Xeris Announces Orange Book Listing of U.S. Patent for Recorlev (Business Wire)
Aug-12-25 12:00PM	Xeris Biopharma (XERS) Upgraded to Buy: Here's Why (Zacks)
09:15AM	Xeris Biopharma Holdings, Inc. (XERS) Hits Fresh High: Is There Still Room to Run? (Zacks)
Aug-07-25 10:30AM	BC-Most Active Stocks (Associated Press Finance) +20.22%
09:30AM	Xeris Biopharma (XERS) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates (Zacks)
08:35AM	Loading…
08:35AM	Xeris Biopharma (XERS) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
07:32AM	Xeris Biopharma: Q2 Earnings Snapshot (Associated Press Finance)
07:00AM	Xeris Biopharma Reports Record Financial Results for the Second Quarter 2025 and Raises Full Year Revenue Guidance (Business Wire)
Jul-31-25 07:30AM	Xeris Biopharma to Report Second Quarter 2025 Financial Results on August 7, 2025 (Business Wire)
Jul-03-25 08:19AM	Zevra Therapeutics (ZVRA) Moves 5.1% Higher: Will This Strength Last? (Zacks)
Jun-03-25 07:30AM	Xeris Unveils Strategy for Long-Term Growth and Value Creation at 2025 Analyst & Investor Day (Business Wire) -7.92%
May-20-25 07:30AM	Xeris Announces Details for Analyst & Investor Day (Business Wire)
May-12-25 03:54PM	Xeris Biopharma Holdings, Inc. (XERS): Among the Unstoppable Growth Stocks to Invest in Now (Insider Monkey)
May-09-25 03:21AM	Xeris Biopharma Holdings Inc (XERS) Q1 2025 Earnings Call Highlights: Record Revenue Growth and ... (GuruFocus.com)
May-08-25 08:20AM	Xeris Biopharma (XERS) Reports Q1 Loss, Tops Revenue Estimates (Zacks) +15.18%
07:17AM	Xeris Biopharma: Q1 Earnings Snapshot (Associated Press Finance)
07:00AM	Xeris Biopharma Reports Record First Quarter 2025 Financial Results (Business Wire)
May-07-25 12:08PM	Xeris Pharmaceuticals Q1 2025 Earnings Preview (Seeking Alpha)
11:51AM	Xeris Biopharma Holdings: Looking For More Growth In Q1 Earnings (Seeking Alpha)
May-05-25 05:30PM	Corcept Therapeutics (CORT) Meets Q1 Earnings Estimates (Zacks) -7.33%
07:00AM	Loading…
May-01-25 07:00AM	Xeris Biopharma to Report First Quarter 2025 Financial Results on May 8, 2025 (Business Wire)
Apr-22-25 06:46PM	Is Xeris Biopharma Holdings Inc. (XERS) the Best Multibagger Penny Stock to Buy According to Billionaires? (Insider Monkey)
Apr-17-25 07:00AM	Bright Peak Therapeutics Appoints John Schmid to its Board of Directors (GlobeNewswire)
Mar-28-25 08:00AM	Xeris Announces Changes to Its Board of Directors (Business Wire)
Mar-27-25 10:18AM	Is Xeris Biopharma Holdings (XERS) The Hot Biotech Stock Under $5? (InsiderMonkey)
Mar-20-25 10:13AM	Strength Seen in Xeris Biopharma (XERS): Can Its 5.6% Jump Turn into More Strength? (Zacks)
Mar-19-25 04:49PM	Xeris Biopharma Holdings (XERS): Among the Best Stocks to Invest in for a Stock Market Game (InsiderMonkey) +5.56%
Mar-17-25 08:00AM	Xeris Announces Approval of Supplemental New Drug Application (sNDA) of Gvoke VialDx (glucagon) for Use as a Diagnostic Aid (Business Wire)
Mar-07-25 02:08AM	Xeris Biopharma Holdings Inc (XERS) Q4 2024 Earnings Call Highlights: Surpassing Revenue ... (GuruFocus.com)
Mar-06-25 09:30AM	Here's What Key Metrics Tell Us About Xeris Biopharma (XERS) Q4 Earnings (Zacks) +9.55%
08:15AM	Xeris Biopharma (XERS) Reports Q4 Loss, Misses Revenue Estimates (Zacks)
07:22AM	Xeris Biopharma: Q4 Earnings Snapshot (Associated Press Finance)
07:00AM	Xeris Biopharma Delivers Record Fourth Quarter and Full-Year 2024 Results; and Announces 2025 Guidance (Business Wire)
Feb-27-25 07:00AM	Xeris Biopharma to Report Fourth Quarter and Full-Year 2024 Financial Results on March 6, 2025 (Business Wire)
Feb-26-25 10:00AM	Xeris Biopharma (XERS) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release (Zacks)
Feb-24-25 08:00AM	Xeris Appoints Anh Nguyen, MD, MBA as Chief Medical Officer (Business Wire)
Feb-05-25 08:00AM	Xeris to Participate in Upcoming Investor Conferences (Business Wire)
Jan-21-25 09:00AM	The American Diabetes Association and Xeris Pharmaceuticals Announce National Collaboration to Provide Life-Saving Hypoglycemia Education and Awareness (PR Newswire)
Jan-11-25 07:27AM	Xeris Biopharma raises FY24 revenue view to $203M from $198M-$202M (TipRanks)
Jan-10-25 07:00AM	Xeris Expects to Exceed Full-Year 2024 Financial Guidance (Business Wire)
Jan-06-25 04:15PM	Xeris Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (Business Wire) -5.37%
Nov-26-24 07:00AM	Xeris to Participate in Piper Sandler 36th Annual Healthcare Conference (Business Wire)
Nov-09-24 02:06AM	Xeris Biopharma Holdings Inc (XERS) Q3 2024 Earnings Call Highlights: Record Revenue Growth and ... (GuruFocus.com)
Nov-08-24 09:30AM	Xeris Biopharma (XERS) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates (Zacks)
08:10AM	Xeris Biopharma (XERS) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
07:10AM	Xeris Biopharma: Q3 Earnings Snapshot (Associated Press Finance)
07:00AM	Xeris Biopharma Reports Third Quarter 2024 Financial Results (Business Wire)
Oct-31-24 08:00AM	Xeris Biopharma to Report Third Quarter 2024 Financial Results on November 8, 2024 (Business Wire)
Oct-04-24 04:05PM	Xeris Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (Business Wire)
Aug-22-24 07:00AM	Xeris to Participate in Upcoming Investor Conferences (Business Wire)
Aug-08-24 08:25AM	Xeris Biopharma (XERS) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
07:30AM	Xeris Biopharma: Q2 Earnings Snapshot (Associated Press Finance)
07:00AM	Xeris Biopharma Reports Second Quarter 2024 Financial Results (Business Wire)
Aug-01-24 10:01AM	Will Xeris Biopharma (XERS) Report Negative Earnings Next Week? What You Should Know (Zacks)
Jul-25-24 07:00AM	Xeris Biopharma to Report Second Quarter 2024 Financial Results on August 8, 2024 (Business Wire) +6.02%
Jul-24-24 09:55AM	Xeris Biopharma (XERS) Now Trades Above Golden Cross: Time to Buy? (Zacks) -5.12%
Jul-08-24 07:00AM	Xeris Biopharma Announces CEO Succession Plan (Business Wire)
Jul-03-24 01:05PM	Xeris Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (Business Wire)
Jun-03-24 07:00AM	Xeris Presents New Post Hoc Analysis on Effects of Levoketoconazole (Recorlev) in Cushings Syndrome Patients at ENDO 2024 (Business Wire) +8.65%
May-30-24 07:30AM	Xeris Biopharma Announces Positive Topline Phase 2 Clinical Data of Its Investigational XeriSol-Formulated Once-Weekly Subcutaneous (SC) Levothyroxine (XP-8121) (Business Wire) +15.03%
07:00AM	Xeris to Participate in the Jefferies Global Healthcare Conference (Business Wire)
May-10-24 03:21PM	Xeris Biopharma Holdings Inc (XERS) Q1 2024 Earnings: Revenue Growth Amidst Challenges (GuruFocus.com) -6.38%
12:36PM	Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Q1 2024 Earnings Call Transcript (Insider Monkey)
12:27AM	Q1 2024 Xeris Biopharma Holdings Inc Earnings Call (Thomson Reuters StreetEvents)
May-09-24 11:55AM	XERS Stock Earnings: Xeris Biopharma Holdings Misses EPS, Misses Revenue for Q1 2024 (InvestorPlace)
08:10AM	Xeris Biopharma (XERS) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
07:11AM	Xeris Biopharma: Q1 Earnings Snapshot (Associated Press Finance)
07:00AM	Xeris Biopharma Reports First Quarter 2024 Financial Results and Recent Events (Business Wire)
May-06-24 07:42AM	Xeris Biopharma Collaborating With Beta Bionics for Development, Commercialization of Glucagon Product (MT Newswires)
07:00AM	Xeris Enters Into an Exclusive Worldwide Collaboration and License Agreement with Beta Bionics (Business Wire)
May-02-24 07:00AM	Xeris Biopharma to Report First Quarter 2024 Financial Results on May 9, 2024 (Business Wire) +6.29%
Apr-03-24 04:05PM	Xeris Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (Business Wire)
Apr-02-24 07:00AM	Xeris Biopharma to Participate in the 23rd Annual Needham Virtual Healthcare Conference (Business Wire)
Mar-07-24 01:47PM	Xeris Biopharma Holdings Inc (XERS) Reports Robust Revenue Growth in Q4 and Full Year 2023 (GuruFocus.com)
11:56AM	Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Q4 2023 Earnings Call Transcript (Insider Monkey)
Mar-06-24 11:16PM	Q4 2023 Xeris Biopharma Holdings Inc Earnings Call (Thomson Reuters StreetEvents) -19.48%
12:52PM	XERS Stock Earnings: Xeris Biopharma Holdings Meets EPS, Beats Revenue for Q4 2023 (InvestorPlace)
08:15AM	Xeris Biopharma (XERS) Reports Q4 Loss, Lags Revenue Estimates (Zacks)
07:17AM	Xeris Biopharma: Q4 Earnings Snapshot (Associated Press Finance)
07:02AM	Xeris Biopharma Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Events (Business Wire)
07:00AM	Xeris Refinances Its $150M Senior Secured Term Loan Facility With Hayfin Capital (Business Wire)
Mar-05-24 09:42AM	Why Xeris (XERS) Might Surprise This Earnings Season (Zacks)
Feb-28-24 07:00AM	Xeris Biopharma to Report Fourth Quarter and Full Year 2023 Financial Results on March 6, 2024 (Business Wire)
Feb-05-24 07:00AM	Xeris to Present at the Oppenheimer 34th Annual Healthcare Life Science Conference (Business Wire)
Jan-11-24 08:30AM	Xeris (XERS) Up on Licensing Deal With Amgen to Develop Tepezza (Zacks)
Jan-10-24 08:00AM	Xeris Biopharma Enters Into an Exclusive Worldwide License Agreement for Xeriject Formulation of Teprotumumab (Business Wire) +16.18%
Jan-08-24 02:48PM	7 Small-Cap Stocks to Best Position Your Portfolio for a Strong 2024 (InvestorPlace)
Jan-05-24 04:05PM	Xeris Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (Business Wire)
Jan-04-24 07:00AM	Xeris Biopharma Updates Its Outlook for 2023 (Business Wire) +12.95%
Dec-27-23 07:00AM	Xeris Biopharma to Present at the 42nd Annual J.P. Morgan Healthcare Conference (Business Wire)

Xeris Biopharma Holdings, Inc. is a biopharmaceutical company, which engages in developing and commercializing products across a range of therapies. The company has three commercial products: Gvoke, Keveyis, and Recorlev. Gvoke is ready-to-use liquid glucagon for the treatment of severe hypoglycemia. Keveyis is the therapy approved in the United States to treat hyperkalemic, hypokalemic, and related variants of primary periodic paralysis (PPP). Recorlev is a cortisol synthesis inhibitor approved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. Its product also includes Ogluo which is used for the treatment of severe hypoglycemia in adults, adolescents, and children aged 2 years and over with diabetes mellitus. The company was founded by Steven Prestrelski in 2005 and is headquartered in Chicago, IL.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
PERSKY MARLA	Director	Sep 11 '25	Sale	7.72	15,500	119,610	142,000	Sep 12 05:09 PM
MARLA PERSKY	Director	Sep 11 '25	Proposed Sale	7.81	15,500	121,055		Sep 11 04:24 PM
SHERMAN JEFFREY W	Director	Aug 28 '25	Option Exercise	6.66	47,040	313,286	261,420	Aug 29 05:21 PM
SHERMAN JEFFREY W	Director	Aug 28 '25	Sale	7.92	42,232	334,515	219,188	Aug 29 05:21 PM
JEFFREY SHERMAN	Director	Aug 28 '25	Proposed Sale	7.92	42,232	334,511		Aug 28 04:09 PM
JOHNSON JOHN	Director	Aug 13 '25	Sale	7.32	107,500	786,459	833,483	Aug 15 04:57 PM
HALKUFF DAWN	Director	Aug 12 '25	Sale	7.28	42,500	309,226	115,000	Aug 13 04:47 PM
JOHN H JOHNSON	Director	Aug 13 '25	Proposed Sale	7.32	107,500	786,452		Aug 13 04:08 PM
DAWN HALKUFF	Director	Aug 12 '25	Proposed Sale	7.28	42,500	309,226		Aug 12 04:23 PM
McCulloch Kevin	See Remarks	Jun 13 '25	Buy	4.38	25,000	109,475	1,708,585	Jun 16 04:26 PM
Fairley Ricki Louise	Director	May 09 '25	Proposed Sale	4.90	56,667	277,668		May 09 05:28 PM
Hecht Beth	See Remarks	Mar 20 '25	Sale	5.43	40,000	217,244	1,353,510	Mar 21 05:31 PM
Hecht Beth	Officer	Mar 20 '25	Proposed Sale	5.14	40,000	205,600		Mar 20 05:26 PM
Pieper Steven	See Remarks	Nov 22 '24	Option Exercise	1.55	19,483	30,199	1,441,820	Nov 26 05:00 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

XERS

Xeris Biopharma Holdings Inc

Upgrade your FINVIZ experience